Loading clinical trials...
Loading clinical trials...
A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia
Conditions
Interventions
MenACWY-CRM
Locations
4
Russia
Federal State Budgetary Institution 'State Scientific Center 'Institution of Immunology' of the Russian Federal Biomedical Agency'
Kashirskoye Highway, Moscow, Russia
Institution of the Russian Academy of Sciences "Scientific Center for Children Health RAMS"
Lomonosovskiy Avenue, Moscow, Russia
Federal Budgetary Institution of Science 'St-Petersburg Scientific-Research Institution of Epidemiology and Microbiology by name of Pasteur'
Mira Street, Sankt-Peterburg, Russia
Federal State Institution 'Scientific-Research Institution of Children's Infections of the Russian Federal Biomedical Agency'
Prof.Popova Street, Sankt-Peterburg, Russia
Start Date
November 1, 2012
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
April 28, 2023
NCT03694405
NCT04358731
NCT01896596
NCT02811120
NCT03089086
NCT01214837
Lead Sponsor
Novartis Vaccines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions